Four years on, the Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, proving to be nothing more ...
Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing secondary and exploratory biomarker endpoints, the biotech has pulled the ...
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.” After ...
Cassava says failed trial results have impacted its second Phase 3 trial, ReFocus-ALZ; decides to discontinue ReFocus-ALZ Cassava says it will continue to review the data and evaluate the next ...
Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...
Residents of Mainstay/Whyaka, Region Two, are now set to become more self-sufficient with the opening of a cassava agro-processing and water purification facility. The milestone was marked by a ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...